Cisplatin (CDDP) and oral vinorelbine (NVBO) concomitantly with radiotherapy (RT) after induction chemotherapy (CT) in locally advanced (LA) non-small cell lung cancer (NSCLC) treatment: Clinical experience in five institutions in Spain.

• DOI: 10.1200/jco.2010.28.15_suppl.7093
• Publication Date: 2017-02-23T21:41:10Z
• Authors: J. Remon; I. Diaz Padilla; J. Andrade; A. Gasco; J. M. Jurado; F. J. Perez; M. P. Lianes
• Keywords: Vinorelbine; Regimen; Concomitant

7093 Background: CDDP+NVBO as induction and concomitant regimen with RT has shown good efficacy outcomes safety profile (Krzakowski, J Thor Oncol. 2008). Five Spanish institutions have collected the data of patients LA NSCLC treated previously reported in order to confirm results clinical daily activity. Methods: Between February 2007 April 2009, 19 chemo-naïve (p) histologically confirmed stage IIIA/IIIB unresectable were treated. Treatment consisted NVBO D1,8 60 mg/m2 cycle (cy) 1 80 cy 2 (if no haematological/non- haematological grade 3-4 toxicity) CDDP every 3 weeks for induction. OR/NC pts received 40 more 60-66 Gy 6.5 weeks. Results: Patient's characteristics were: Median age, 61 years (range 50-76); all males; smokers, 79%; adenocarcinoma, 42% / squamous, 26%; IIIA, 5% IIIB, 95%. 17 p completed 4 treatment; was cancelled after due neutropenia, died (due disease). We analyzed 72 cy. Hematological toxicities (% cy): (g) 3/4 9.7%; g3 anemia, 1.4%. Non-hematological oesophagitis g 3/4, 1.4%; constipation g4, fever g3, infection 4.2%. No nausea or vomiting reported. evaluable response. 13 PR (76.5%) SD (11.8%) Survival analysis not been performed short follow-up. Conclusions: The findings this retrospective plus when administered concurrently p. excellent tolerance allowed complete CT/RT treatment 90% pts. significant financial relationships disclose.